What is Sonavex?
Sonavex is a specialized medical technology firm focused on the development of automated 3D ultrasound solutions designed to enhance the precision of dialysis access procedures. The company's core product suite, which includes EchoMark, EchoSure, and EchoMap, provides clinicians with real-time, actionable data regarding blood flow and fistula maturation. By integrating advanced visualization capabilities into standard clinical workflows, Sonavex addresses significant pain points for dialysis access teams, ultimately reducing complications and improving the economic efficiency of patient care. Their multidisciplinary approach combines engineering excellence with clinical rigor, establishing the firm as a pivotal player in the intersection of diagnostic imaging and chronic disease management.
How much funding has Sonavex raised?
Sonavex has raised a total of $12.4M across 6 funding rounds:
Angel/Seed
$1M
Private Equity
$2.2M
Grant
$750K
Series A
$2.2M
Unspecified
$3M
Debt
$150K
Angel/Seed (2015): $1M, investors not publicly disclosed
Private Equity (2016): $2.2M, investors not publicly disclosed
Grant (2017): $750K supported by National Science Foundation
Series A (2017): $2.2M featuring Grey Sky Venture Partners, Tedco, CRCM Venture Capital, and the Abell Foundation
Unspecified (2019): $3M backed by Texas Medical Center
Debt (2020): $150K with participation from PPP
Key Investors in Sonavex
Grey Sky Venture Partners
Grey Sky Venture Partners provides comprehensive tools and strategic resources for planning and executing large-scale operations, offering professional-grade support to foster growth and operational efficiency.
Tedco
TEDCO is the Maryland Technology Development Corporation, dedicated to fostering an inclusive entrepreneurial ecosystem by investing in and growing technology and life science-based companies.
CRCM Venture Capital
CRCM Venture Capital is a San Francisco-based registered investment adviser providing tailored financial strategies and professional investment management for institutions and individuals.
What's next for Sonavex?
With the recent influx of capital, Sonavex is poised to transition into a phase of accelerated commercialization and product iteration. The strategic focus will likely center on expanding the clinical adoption of its Echo platform, targeting larger health systems that prioritize data-driven patient outcomes. As the company matures, the emphasis will shift toward scaling manufacturing capabilities and deepening its research into new applications for its ultrasound technology. By maintaining a focus on both clinical efficacy and economic value, Sonavex is strategically positioned to capture a larger share of the vascular access market, potentially setting new benchmarks for standard-of-care protocols in dialysis and related surgical interventions.
See full Sonavex company page
